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Introduction
Cardiovascular diseases are closely related to several risk factors such as high blood pressure,
obesity, high blood levels of cholesterol and triglycerides and insulin resistance and are the
major cause of death in adults and the elderly in the majority of the developed countries. The
risk of cardiovascular disease can be reduced through pharmacological treatment, however to
achieve that, most patients require a combined cardiovascular medication involving different
drug classes which have different targets and mechanisms of action to regulate each factor
separately. In the case of several compounds used in combined cardiovascular therapy, it is
very important to monitor the blood concentrations of drugs to understand their
pharmacokinetics and pharmacodynamics and also to detect misuse of these drugs to reveal
accidental or intentional intoxications. [1-3] Therefore, the development of an assay that can
detect a range of cardiovascular medications using a single small sample may be of great
importance in the forensic context.
The aim of this work was to develop a versatile analytical method that allows the simultaneous
identification of several different substances used for cardiovascular diseases treatment in
putrefied specimens collected in the context of an exhumation performed several decades after
death. For this purpose an UPLC-MS/MS method was developed for the qualitative analysis of
26 substances that included: anticoagulants; angiotensin converting enzyme inhibitors;
angiotensin II receptor blockers; beta-blockers; calcium channel blockers; diuretics; statins;
vasodilators and others. During autopsy, in spite of the corpse was partially mummified it was
possible to collect body tissues from different anatomic regions, namely: encephalic mass,
heart, lungs, liver, stomach, kidney, bladder and colon.
Conclusions
The analysis of a collection of substances with different physicochemical properties and a wide
range of expected concentrations in biological matrices represents a challenge due to the
difficulty of developing a proper extraction procedure and an analytical method adequate for all
the analytes detection. That challenge is even higher when the biological samples are not
conventional matrices such as the putrefied specimens collected from an exhumation autopsy, as
presented in this work. The UPLC-MS/MS method developed together with a very simple sample
preparation procedure showed adequate levels of performance with recovery range from 48% to
107% and LOD values in the range of 0.05 – 50 ng/mL for all the substances, except for the
methyldopa with estimated LODs that ranged from 70 - 500 ng/mL.Results
Due to the high complexity and uniqueness of the specimens analyzed the method was
assessed in terms of the recovery and limits of detection (LOD) using the standard addition
method. The results obtained for the LODs and recovery are presented in table 2.
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Experimental
Sample Preparation
Each sample was previously diluted, homogenized and subjected to a sample precipitation
procedure according to the following figure:
Table 1. MRM transitions, cone voltage, collision energy and retention time (RT) of the analytes 
and internal standards (IS).
UPLC-MS/MS
 Equipment: Waters Acquity UPLC/TQ Detector (Triple quadrupole mass spectrometer).
 Column: Acquity UPLC® HSS T3 (100 mm x 2.1 mm i.d., 1.8 µm).
 Mobile phase: Solvent A – ACN; Solvent B – Ammonium formate 2 mM (0.1% HCOOH).
 Flow: 0.3 mL/min.
 Gradient: 5% (A); 5-65% (A) in 3.5 min; 65-95% (A) in 4.5 min; 95%(A) for 2 min; 95-5% (A)
in 0.1 min; 5% (A) for 2.4 min.
 Ionization/Acquisition mode: ESI +/- ; MRM (see table 1)
Figure 1.Sample preparation procedure
LOD (ng/mL) Rec. (%)
Substance S1 S2 S3 S4 S5 S6 S7 S8
Methyldopa 180 70 140 250 280 440 330 500 48
Ethylephrine 5 15 5 50 25 20 40 40 71
Atenolol 0.7 3.3 1.5 5 5 1.5 5 5 74
Lisinopril 1.8 4.3 5 5 5 5 5 5 55
Clonidine 50 50 50 >50 >50 >50 >50 >50 82
Hydrochlorothiazide 5 5 5 5 5 5 5 5 73
Triamterene 2 5 5 5 5 5 15 5 73
Propanolol 1 5 5 20 3,6 20 15 5 83
Enalapril 0.8 2.2 1.8 1.8 1.4 1.8 1.5 1.4 76
Diltiazem 0.2 5 5 5 1.4 5 15 5 85
Digoxin 2.5 5 5 5 5 5 4.1 5 83
Carvedilol 2.8 15 5 30 5 5 25 0.3 83
Pravastatin 0.6 1.2 0.6 1.5 0.2 0.5 0.9 0.3 84
Furosemide 5 5 2.7 5 4.4 4.2 5 3 80
Ramipril 0.2 1.9 1.2 1.2 1.2 1 1 1.3 79
Verapamil 0.2 1 1.3 5 0.9 2.2 5 5 83
Reserpine 1.2 5 5 25 2.1 5 7.4 50 76
Methyldigoxin 2.3 5 5 5 5 5 5 4 81
Losartan 1.2 2 1.9 3.6 0.9 1.9 0.9 1.7 85
Temilsartan 0.4 3.1 1.4 2.8 0.8 2.7 2.8 2.6 93
Nifedipine 0.6 0.6 0.3 0.9 0.5 0.3 0.1 0.3 75
Valsartan 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.2 54
Warfarin 0.1 0.2 0.1 0.2 0.1 0.05 0.05 0.1 82
Atorvastatin 0.5 2.4 0.5 1.8 0.6 2.2 0.6 0.4 95
Lovastatin 0.6 1 0.5 0.7 1.2 2.4 1.5 4 107
Simvastatin 0.8 0.5 0.6 1.2 0.2 1.3 0.9 5 79
Table 2. Results obtained for the limit of detection (LOD) for the samples: S1 (encephalic mass); 
S2 (heart); S3 (lung); S4 (liver); S5 (stomach); S6 (kidney); S7 (bladder) and S8 (colon) and for 
the recovery.
Substance ESI (+/-) MRM Transitions (m/z) Cone (V) Collision (eV) RT (min)
Methyldopa + 212.0 > 139.1/166.1 25 16 1.15
Ethylephrine + 182.0 > 91.2/164.1 25 22/12 1.33
Atenolol + 267.0 > 145.2/190.1 40 26/20 1.50
Lisinopril + 406.1 > 84.2/246.2 45 24/20 1.83
Clonidine + 230.0 > 44.3/160.1 40 36 1.91
Hydrochlorothiazide - 296.0 > 205.0/269.0 40 24/18 2.10
Triamterene + 254.0 > 104.1/237.1 60 36/28 2.11
Sulfameter (IS) + 281.0 > 108.0 35 22 2.52
Propanolol + 260.0 > 116.2/183.1 40 18 3.02
Enalapril + 377.1 > 234.2/303.1 30 20 3.03
Diltiazem + 415.0 > 178.0/370.0 40 24/16 3.30
Digoxin + 798.3 > 651.0/781.0 25 12 3.35
Carvedilol + 407.0 > 100.2/283.2 40 28/20 3.40
Pravastatin - 423.1 > 101.2/321.2 40 24/16 3.40
Furosemide - 329.0 > 205.0/285.0 40 20/14 3.48
Ramipril + 417.1 > 234.2/343.2 30 22 3.54
Verapamil + 455.2 > 165.2/303.0 50 28 3.64
Reserpine + 609.3 > 195.2/397.1 60 34/28 3.77
Methyldigoxin + 812.3 > 651.0/795.0 25 12 3.89
Losartan + 423.0 > 207.1/405.1 30 12/24 3.92
Temilsartan + 515.1 > 276.2/497.1 45 46/38 4.05
Nifedipine + 347.0 > 271.1/315.0 20 12/8 4.37
Valsartan + 436.1 > 235.1/291.1 30 16 4.41
Oleandrin (IS) + 577.4 > 373.1 30 14 4.48
Warfarin + 309.0 > 163.0/251.0 30 14/18 4.61
Atorvastatin + 559.1 > 292.1/440.1 40 26 4.83
Lovastatin + 405.1 > 199.2/285.1 25 12 6.32
Simvastatin + 419.1 > 199.2/285.2 40 12 6.91
